JACC’s November 4 issue features the High Blood Pressure Guideline surrounded by a series of expert commentaries. In this video interview, JACC Deputy Editor Erica S. Spatz, MD, FACC, speaks with author Anand Vaidya, MD MMSc. Listen in for an insider view of the evolving understanding of primary aldosteronism in light of the 2025 high blood pressure guidelines. Dr. Vaidya emphasizes that primary aldosteronism may be a common, modifiable contributor to hypertension—potentially affecting up to 25% of patients—and advocates for simplified diagnostic approaches and broader use of mineralocorticoid receptor antagonists to improve outcomes.

Abstract. Primary aldosteronism(PA) is the most common endocrine hypertension. For decades, PA diagnosis has required proving non-suppressibility of aldost

Pheochromocytomas and paragangliomas (PPGLs) are rare chromaffin cell-derived neuroendocrine tumors of sympathetic (catecholamine-producing) or parasympathetic (nonsecretory) origin, frequently driven...

Background: Confirmatory tests are recommended for diagnosing primary aldosteronism, but the supporting evidence is unclear. Methods: We searched Medline, EMBASE, and the Cochrane Central Register o...

This interactive feature describes a woman who received a diagnosis of hypertension and preeclampsia at 27 years of age. After giving birth, her blood pressure remained elevated. Test your diagnost...